Mechanism of Action
HIV Fusion Inhibition
Albuvirtide is derived from the heptad repeat 2 (HR2) region of HIV-1 gp41 transmembrane protein. During viral entry, gp41 undergoes a conformational change that drives membrane fusion. Albuvirtide binds the complementary HR1 region and prevents the formation of the six-helix bundle structure required for membrane fusion, blocking viral entry into CD4+ T cells.
Albumin Binding for Long Half-Life
A fatty acid chain is conjugated to the peptide backbone, enabling non-covalent binding to circulating albumin. This albumin association dramatically extends the plasma half-life from hours (for unmodified gp41-derived peptides) to 11-12 days, enabling once-weekly intravenous dosing in clinical practice.
Research Summary
Phase 3 Trials in China
Approved (China)Phase 3 trials demonstrated non-inferiority of albuvirtide plus lopinavir/ritonavir versus efavirenz-based regimens in treatment-naive HIV-1 patients. At 48 weeks, 79.3% of albuvirtide patients achieved viral suppression (<50 copies/mL) versus 79.7% on efavirenz. CD4+ T cell recovery was comparable between arms.
Salvage Therapy
ClinicalIn treatment-experienced patients with multidrug resistance, albuvirtide combined with optimized background therapy demonstrated significant viral suppression. The fusion inhibitor mechanism is active regardless of resistance to NRTIs, NNRTIs, or PIs, making it valuable for salvage regimens.
Calculate your Albuvirtide dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| HIV-1 treatment (approved) | 320 mg | Once weekly | Intravenous infusion |
| Salvage combination therapy | 320 mg + OBT | Once weekly | IV + oral |
Approved in China only. Not available in US/EU markets as of 2025.
Interactions
Safety Profile
Albuvirtide is generally well tolerated. Common adverse effects include injection site reactions, diarrhea, nausea, and dizziness. Unlike enfuvirtide (subcutaneous), IV administration eliminates injection site nodules. Liver enzyme elevations have been reported. No significant QTc prolongation or hematologic toxicity identified in trials.
References
- [1]Su B et al. (2020). Albuvirtide as part of a combination antiretroviral therapy in HIV-infected patients: a systematic review. HIV Medicine, 21(3), 181-192.
- [2]Zhang X et al. (2016). Albuvirtide: a long-acting HIV-1 fusion inhibitor. Antiviral Research, 126, 56-64.